Key Takeaways
- Zealand Pharma shares plummeted approximately 25% following Phase III survodutide trial results revealing substantial patient dropout rates
- Discontinuation rates ranged from 23% to 25% among patients receiving survodutide, primarily due to digestive system adverse events, compared with only 5.4% for placebo recipients
- The medication demonstrated substantial efficacy with weight reduction reaching 16.6% versus 3.2% among placebo patients
- Goldman Sachs analysts cautioned that poor tolerability will probably restrict commercial adoption in the weight management sector
- Wolfe Research maintained its positive stance with a DKK750 target price, suggesting potential upside exceeding 129% from pre-decline valuations
Zealand Pharma (ZEAL) experienced a devastating selloff on Monday, shedding roughly one-quarter of its market capitalization after revealing Phase III clinical data for survodutide—its obesity treatment developed jointly with Boehringer Ingelheim—which demonstrated that approximately 25% of trial participants discontinued therapy due to adverse reactions.
Shares declined roughly 25% during Copenhagen market hours. Novo Nordisk, Zealand’s primary competitor in the weight management pharmaceutical space, also experienced a decline of approximately 2% during the session.
The SYNCHRONIZE-1 clinical study enrolled 725 adult participants with obesity or elevated body weight without diabetes mellitus over a 76-week period. Weight reduction achieved up to 16.6% on the efficacy estimand compared with 3.2% among placebo recipients—representing impressive headline numbers.
However, the safety and tolerability profile painted a more concerning picture.
Patient withdrawal rates reached 23.7% and 24.8% for the 3.6mg and 6mg dosing regimens respectively, in stark contrast to merely 5.4% among placebo participants. The primary driver: gastrointestinal adverse events, which accounted for 17.8% and 20.2% of discontinuations at each dosing level versus only 2.9% in the placebo group.
Goldman Sachs analysts directly addressed the concerning figures, indicating that suboptimal tolerability will probably constrain how extensively survodutide penetrates the obesity treatment marketplace.
Wolfe Research identified an additional confounding factor. Approximately 16.5% of placebo-arm participants utilized a prohibited GLP-1 receptor agonist medication during the study period, which artificially elevated placebo-group weight reduction and diminished the apparent treatment advantage.
The research firm also highlighted how the study’s inflexible protocol design contributed to elevated discontinuation figures, referencing investigator commentary regarding the conflict between maintaining rigid versus adaptable trial parameters.
Impressive Efficacy Findings Provide Some Reassurance
Notwithstanding the adverse event challenges, the effectiveness data contained noteworthy positive elements.
A body composition substudy utilizing MRI technology in 75 participants demonstrated that survodutide 6mg achieved a 34% relative decrease in visceral adipose tissue versus 11.8% for placebo. Hepatic fat content decreased 63.1% compared with 24.5% for placebo recipients, and lean tissue comprised no more than 10.8% of total mass alteration at the maximum dosage.
The companion SYNCHRONIZE-MASLD study, conducted over 48 weeks involving 218 adults with obesity and metabolic-associated liver disease, similarly produced encouraging results. Up to 84.2% of survodutide-treated patients achieved at least a 30% relative hepatic fat reduction, compared with 24.3% receiving placebo. Body weight decreased 12.2% versus 1% among placebo participants.
What Remains for Zealand Moving Forward
Zealand Pharma maintains eligibility for high single-digit to low double-digit percentage royalties on worldwide survodutide commercial sales, in addition to €315 million in remaining potential milestone compensation. Boehringer Ingelheim retains complete accountability for clinical development and commercial operations.
Wolfe Research preserved its “outperform” investment recommendation with a DKK750 valuation target—representing approximately 130% potential appreciation from the pre-decline closing price.
Separately, Novo Nordisk announced that prescription volumes for its Wegovy oral weight-loss medication have surpassed three million since the tablet formulation became available in early January.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
